262 related articles for article (PubMed ID: 20014005)
1. PELP1: A novel therapeutic target for hormonal cancers.
Chakravarty D; Tekmal RR; Vadlamudi RK
IUBMB Life; 2010 Mar; 62(3):162-9. PubMed ID: 20014005
[TBL] [Abstract][Full Text] [Related]
2. Emerging significance of ER-coregulator PELP1/MNAR in cancer.
Nair S; Vadlamudi RK
Histol Histopathol; 2007 Jan; 22(1):91-6. PubMed ID: 17128415
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR.
Rajhans R; Vadlamudi RK
Clin Exp Metastasis; 2006; 23(1):1-7. PubMed ID: 16826428
[TBL] [Abstract][Full Text] [Related]
4. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR.
Vadlamudi RK; Kumar R
Nucl Recept Signal; 2007 May; 5():e004. PubMed ID: 17525794
[TBL] [Abstract][Full Text] [Related]
5. Extranuclear coactivator signaling confers insensitivity to tamoxifen.
Kumar R; Zhang H; Holm C; Vadlamudi RK; Landberg G; Rayala SK
Clin Cancer Res; 2009 Jun; 15(12):4123-30. PubMed ID: 19470742
[TBL] [Abstract][Full Text] [Related]
6. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.
Chakravarty D; Nair SS; Santhamma B; Nair BC; Wang L; Bandyopadhyay A; Agyin JK; Brann D; Sun LZ; Yeh IT; Lee FY; Tekmal RR; Kumar R; Vadlamudi RK
Cancer Res; 2010 May; 70(10):4092-101. PubMed ID: 20460518
[TBL] [Abstract][Full Text] [Related]
7. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
9. PELP1: Structure, biological function and clinical significance.
Sareddy GR; Vadlamudi RK
Gene; 2016 Jul; 585(1):128-134. PubMed ID: 26997260
[TBL] [Abstract][Full Text] [Related]
10. Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.
Nagpal JK; Nair S; Chakravarty D; Rajhans R; Pothana S; Brann DW; Tekmal RR; Vadlamudi RK
Mol Cancer Res; 2008 May; 6(5):851-61. PubMed ID: 18505929
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
[TBL] [Abstract][Full Text] [Related]
12. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation.
Manavathi B; Nair SS; Wang RA; Kumar R; Vadlamudi RK
Cancer Res; 2005 Jul; 65(13):5571-7. PubMed ID: 15994929
[TBL] [Abstract][Full Text] [Related]
13. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
Nair BC; Nair SS; Chakravarty D; Challa R; Manavathi B; Yew PR; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2010 Sep; 70(18):7166-75. PubMed ID: 20807815
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.
Habashy HO; Powe DG; Rakha EA; Ball G; Macmillan RD; Green AR; Ellis IO
Breast Cancer Res Treat; 2010 Apr; 120(3):603-12. PubMed ID: 19495959
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.
Vadlamudi RK; Balasenthil S; Broaddus RR; Gustafsson JA; Kumar R
J Clin Endocrinol Metab; 2004 Dec; 89(12):6130-8. PubMed ID: 15579769
[TBL] [Abstract][Full Text] [Related]
17. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha.
Vadlamudi RK; Wang RA; Mazumdar A; Kim Y; Shin J; Sahin A; Kumar R
J Biol Chem; 2001 Oct; 276(41):38272-9. PubMed ID: 11481323
[TBL] [Abstract][Full Text] [Related]
19. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL; Freedman OC; Howell A; Clemons M
Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
[TBL] [Abstract][Full Text] [Related]
20. The social network of PELP1 and its implications in breast and prostate cancers.
Gonugunta VK; Miao L; Sareddy GR; Ravindranathan P; Vadlamudi R; Raj GV
Endocr Relat Cancer; 2014 Aug; 21(4):T79-86. PubMed ID: 24859989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
